Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New spinal implant studied for osteoporosis fractures

NCT ID NCT05337696

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new device called the Vertebral Implant PEEK (VIP) for people with spine fractures due to osteoporosis. The goal was to see if the implant is safe and helps repair the broken bone. The study included 23 adults aged 50 and older with recent fractures that did not get better with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

May 2022

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 50 * Osteoporotic compression fractures of the thoracolumbar spine (T1 -L5) * Up to three levels can be fractured and treated, but at least one of the three need to be treated with V-STRUT; the level(s) to be treated with study device is at the discretion of the enrolling investigator * Fracture age of ≤ 12 weeks as indicated by onset of pain or known antecedent traumatic event with corresponding evidence of acuity on MRI (T1 and STIR sequences) or radioisotope bone scan * ODI ≥ 30/100 at screening visit and VAS ≥ 60 at screening visit * Failure of conservative management strategies for compression fractures resulting in inadequately controlled pain and/or patient immobility * Patient has failed non-operative medical therapy as defined by one of the following definitions set forth by the American College of Radiology: 1. For a patient rendered nonambulatory as a result of pain from a VCF, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy; or 2. For a patient with sufficient pain from a VCF such that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or 3. For a patient with pain from a VCF, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level. * Magerl classification A1.1, A1.2, A1.3, A2.1, A2.2 and A3.1 type fractures: pediculosomatic junction fractures and other fractures involving vertebral pedicles * Appropriate pedicle diameter to receive 4.5mm, 5.5mm diameter or 6.5mm diameter implants * ASA \< 4 Exclusion Criteria: * Patient clearly improving on conservative treatment * Any contra-indication or allergy to implant material or cement * Systemic infection or infection located in the spine * Any medical condition including but not limited to anemia, coagulation disorders, fibromyalgia, algoneurodystrophy, Paget's disease, uncontrolled diabetes that would preclude the patient from having surgery or would impede the benefit of surgery * Neurologic signs or symptoms related to the fracture or the impeding pathological fracture * Any previous surgical treatment (material or cement) in the targeted vertebra * Less than one third of the original vertebral body height remaining * Unstable fractures or neoplasms with posterior involvement * Damages of the posterior wall * Sclerotic cancellous bone * Pedicles not large enough to accept V-STRUT© instrumentation and implants * Pregnancy(women of childbearing potential must have a negative pregnancy test to participate) * Pre-existing or clinically unstable neurologic deficit * Spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated * Any physical exam evidence of myelopathy or radiculopathy * Pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis) * Bedbound prior to incident fracture * Spondylolisthesis \>Grade 1 at target VB * Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.) * A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant or anti-aggregate (anti-platelet agents) on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count \> 100,000) * Disabling backpain due to causes other than acute fracture * Severe cardiopulmonary deficiencies * Any evidence of alcohol or drug abuse * Uncontrolled psychiatric illness or severe dementia * Involved in medical litigation including workers' compensation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporotic vertebral compression fractures are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • St. Luke's

    Bethlehem, Pennsylvania, 18015, United States

  • West Virginia

    Morgantown, West Virginia, 26506, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.